Wednesday, July 8, 2026

pharma · NASH With Fibrosis · NASH - Nonalcoholic Steatohepatitis · HEPA

Hepion Pharmaceuticals

Hepion Pharmaceuticals is a pharma organization headquartered in Morristown, USA. It trades on NYSE under ticker HEPA. Primary therapeutic focus areas include NASH With Fibrosis, NASH - Nonalcoholic Steatohepatitis, Hepa

Morristown, USA HQ
4 Employees
Public company Type
HEPA · NYSE Ticker
Company details
Status
Public
HQ
Morristown, USA
Employees
4
Programs
5
Drugs
2
Patents
1
Clinical program

CRV431 75mg

Phase 2 · small molecule · NASH - Nonalcoholic Steatohepatitis

CRV431 75mg for NASH - Nonalcoholic Steatohepatitis is a Phase 2 program (small_molecule) at Hepion Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All Hepion Pharmaceuticals projects Phase 2 small molecule completed

Internal code HEPA-CRV431-201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hepion Pharmaceuticals
Phase
Phase 2
Modality
small_molecule
Indication
NASH - Nonalcoholic Steatohepatitis
Status
completed
Trials
1